Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PfSPZ-CVac Dose Escalation in Healthy Adults
NCT02773979Phase 1Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Sep 2016
- Primary completion
- Jan 2018
- Modality
- Live Biotherapeutic Products, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of PfSPZ Challenge in malaria (3 arms), sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoints: Serious Adverse Events related to study product, Solicited Local Adverse Events and 5 more. Started Sep 2016; status: completed.
02
Drugs
PfSPZ Challenge
03
Conditions
malaria
Beyond the preview
Go deeper on NCT02773979.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02773979.